Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 3;16(1):92.
doi: 10.1186/s13045-023-01489-3.

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Juanjuan Zhao #  1 , Quan Ren #  1 , Xinyuan Liu  2 , Xiangqian Guo  2 , Yongping Song  3
Affiliations

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting

Juanjuan Zhao et al. J Hematol Oncol. .

Abstract

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.

Keywords: BCMA; Bispecific antibody; FcRH5; GPRC5D; Multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Moreau P, Garfall AL, Bhutani M, Oriol A, Nooka AK, Martin TG, Rosiñol L, Mateos M-V, Bahlis NJ, Popat R, Besemer B, Martinez-Lopez J, Krishnan AY, Delforge M, Trancucci D, Verona R, Stephenson T, Chastain K, Sidana S. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) J Clin Oncol. 2023;41(16_suppl):8011–8011. doi: 10.1200/JCO.2023.41.16_suppl.8011. - DOI
    1. Shekarkhand T, Patel D, Tan CRC, Hultcrantz M, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Korde N, Maclachlan K, Landau HJ, Scordo M, Chung DJ, Shah GL, Lahoud OB, Giralt S, Usmani SZ. Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies. J Clin Oncol. 2023;41(16_suppl):8049–8049. doi: 10.1200/JCO.2023.41.16_suppl.8049. - DOI
    1. Hungria VT, Bhutani D, Landgren O, Vieyra D, Guo Y, Verona R, Miao X, Qi M, Watkins L, Shah P, Chastain K, Qi M, Quach H. MajesTEC-9: a randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41(16_suppl):8067–8067. doi: 10.1200/JCO.2023.41.16_suppl.TPS8067. - DOI
    1. Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, Rodríguez-Otero P, Martinez-Lopez J, Koehne G, Jethava Y, Gabayan AE, Stevens DA, Nooka AK, Raje NS, Iida S, Leip E, Conte U, Czibere AG, Viqueira A, Lesokhin AM. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study. J Clin Oncol. 2023;41(16_suppl):8039–8039. doi: 10.1200/JCO.2023.41.16_suppl.8039. - DOI
    1. Yeh S-P, Huang JSY, Byun JM, DiRienzo C, Viqueira A. MagnetisMM-6: an open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) J Clin Oncol. 2023;41(16_suppl):TPS065–TPS8065.

Publication types

MeSH terms

Substances